Daniel Silver, MD

Daniel P. Silver, MD, PhD

Contact Dr. Silver

233 S. 10th Street
Philadelphia, PA 19107

(215) 955-2054
(215) 955-5391 fax

Most Recent Peer-reviewed Publications

  1. Overexpression of BLM promotes DNA damage and increased sensitivity to platinum salts in triple-negative breast and serous ovarian cancers
  2. Zoledronic acid alters hematopoiesis and generates breast tumor-suppressive bone marrow cells
  3. MECP2 is a frequently amplified oncogene with a novel epigenetic mechanism that mimics the role of activated RAS in malignancy
  4. BRCA1 pathway function in basal-like breast cancer cells
  5. Mechanisms of BRCA1 tumor suppression
  6. Mutational processes molding the genomes of 21 breast cancers
  7. Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents
  8. Chek2 DNA damage response pathway and inherited breast cancer risk
  9. Poly ADP-ribose polymerase inhibitors: Science and current clinical development
  10. Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers
  11. Poly(ADP-ribose) polymerase inhibition: "Targeted" therapy for triple-negative breast cancer
  12. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer
  13. Complex landscapes of somatic rearrangement in human breast cancer genomes
  14. Estrogen receptor-negative breast cancer: New insights into subclassification and targeting
  15. Cyclin A Is Redundant in Fibroblasts but Essential in Hematopoietic and Embryonic Stem Cells
  16. Synthetic lethality - A new direction in cancer-drug development
  17. Cancer: Crossing over to drug resistance
  18. Further Evidence for BRCA1 Communication with the Inactive X Chromosome
  19. Abnormalities of the inactive X chromosome are a common feature of brca1 mutant and sporadic basal-like breast cancer
  20. Endogenous oncogenic K-rasG12D stimulates proliferation and widespread neoplastic and developmental defects